Afaxys Pharmaceuticals Introduces New Generic, Oral Contraceptive; Aubra(TM) Extends Company's Mission to Serve Safety Net Health Providers

CHARLESTON, SC--(Marketwired - Oct 29, 2013) - Afaxys Pharmaceuticals, a division of Afaxys, Inc. (afaxys.com), is dedicated to providing affordable health care products to the public health care sector. The company continues this mission with the FDA approval of this new generic oral contraceptive.

Available only to the public health sector (including family planning clinics; college and university health centers; community health centers; and city, county, state, and federal facilities), and authorized, non-retail prescribers,

Aubra™ /AW•bruh/ (Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.1mg/0.02mg) is an AB rated, generic contraceptive. 

• Aubra is AB rated to Lutera® and compares to these monophasic regimens: Sronyx®, Aviane®, Falmina®, Lessina®, Levlite®, and Orsythia®.

This new Afaxys product is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive for contraception. This product does not protect against the transmission of HIV (AIDS) and other sexually transmitted diseases. Cigarette smoking increases the risk of serious cardiovascular disease. Women who use oral contraceptives should be strongly advised not to smoke. Please see full prescribing information here [https://pharma.afaxys.com/afaxys/assets/pdf/Aubra_PI.pdf].

The approval of Aubra is an important step in the Afaxys Pharmaceuticals mission to provide a reliable, affordable supply of contraceptives for women who rely on safety net providers; family planning clinics; college and university health centers; community health centers; and city, county, and state providers for their healthcare. Aubra is the one of several monophasic oral contraceptives approved for inclusion into the ever expanding Afaxys core formulary selected by, and for, safety-net providers and their patients.

Afaxys Pharmaceuticals is a division of Afaxys, Inc., a company whose core mission is to serve the public health sector with low priced, readily available mission-critical products. Prior to Afaxys Pharmaceuticals' market entry, public health clinics faced unexpected price increases and fluctuating product availability, which made it difficult to plan and deliver services to patients. Afaxys Pharmaceuticals utilizes a 'dual sourcing strategy' which means that if one manufacturer should experience delays or disruptions, Afaxys is able to provide products from another source so it can deliver products to customers when they need them. 

Note: This press release was issued in the United States and is intended as reference information for U.S. journalists and customers. The information contained in each Afaxys press release was accurate at the time of issuance, and the company assumes no responsibility for updating the information to reflect subsequent developments.